ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility
The FDA has approved ADMA Biologics Inc's (NASDAQ: ADMA) BioCenters plasma collection facility in Maryville, Tennessee.
The plasma collection facility commenced operations and initiated source plasma collection in Q4 of 2020.
With today's approval, the facility is now licensed to collect and introduce into interstate commerce human source plasma for further manufacturing in the U.S.
ADMA has eight plasma collection facilities, including three FDA-approved facilities. Five of those facilities are now open and collecting plasma, and two additional marketing applications are anticipated over the remainder of 2021.
In total, ADMA remains on track to have 10 or more FDA-approved plasma collection facilities by 2024.
Price Action: ADMA shares are up 13.4% at $1.69 during the premarket session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.
See more from Benzinga
Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
Enlivex Therapeutics Stock Jumps On Initiation Of Another Mid-Stage COVID-19 Trial
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.